Rewind raises fresh funding for oral myelin-repair drug in MS
What's the deal? Belgium's Rewind Therapeutics has secured additional financing to advance its lead GPR17 antagonist program, an oral therapy designed to repair myelin and restore neurological function in multiple sclerosis (MS). Backers include the Boehringer Ingelheim Venture FundDealroom has a profile for this one. Try Dealroom →, CD3, Gemma Frisius Fonds, Golgi NeurosciencesDealroom has a profile for this one. Try Dealroom →, KU Leuven, M VenturesDealroom has a profile for this one. Try Dealroom →, PMVDealroom has a profile for this one. Try Dealroom →, and Sunstone Life Science VenturesDealroom has a profile for this one. Try Dealroom →.
What's the endgame? Rewind develops small-molecule therapies to restore myelin, the protective coating around nerve fibers damaged in demyelinating diseases. The company plans to complete IND-enabling studies and push its lead program toward clinical development.
Why it matters: Current MS therapies control inflammation but none are approved to restore lost myelin and repair damaged nerves. Rewind is targeting that gap with a disease-modifying oral treatment.
Why now? In July 2026, Rewind and collaborators at the Netherlands Institute for NeuroscienceDealroom has a profile for this one. Try Dealroom → and Amsterdam UMCDealroom has a profile for this one. Try Dealroom → published peer-reviewed data in PLOS ONE . Once-daily oral treatment with a selective GPR17 antagonist accelerated remyelination and improved functional outcomes in preclinical models.
Post-mortem analysis of human MS tissue showed GPR17-expressing cells accumulate in demyelinated lesions, while repaired lesions had little or none — supporting GPR17 as a negative regulator of myelin repair.
What they're saying: "The recent data support both the biology and therapeutic potential of GPR17 antagonism and strengthen our confidence as we advance the program towards clinical development," said Jim Van heusden, executive chair of Rewind.
Chief scientific officer Irene Knuesel noted the treatment improved "both nerve conduction along the visual pathway and cognitive performance," adding that emerging evidence points to a broader role for GPR17 in metabolic regulation, including obesity.
The signal: Myelin repair remains one of the clearest unmet needs in MS, where existing drugs manage symptoms but not nerve damage. Rewind's push toward the clinic — backed by corporate and academic investors — tests whether oral remyelination can move from preclinical promise to treatment.
Read more: finance.yahoo.com
Image credit: National Institutes of Health (NIH)
